Development & Manufacturing

Reliable AAV experiments start with a well-characterized vector. Learn how Vector Biolabs approaches AAV quality and QC to help researchers stay on target from the very start.

This blog was written by SandboxAQ, who provide a comprehensive, end-to-end drug discovery approach powered by Large Quantitative Models (LQMs) derived from AI and physics. Their advanced process enables faster, more accurate development of small molecules and biologics from early-stage research straight through to clinical candidate selection.

‍This Tech Snapshot was written by Artis BioSolutions, an end-to-end cell and gene therapy partner providing synthetic DNA starting material, viral vector manufacturing (AAV and LVV), and cell therapy manufacturing under one roof.

Molecular glues enable targeting of previously undruggable proteins by promoting protein-protein interactions, potentially treating diseases unresponsive to conventional small-molecule drugs through degradation, stabilization, or functional activation mechanisms. Discovery and validation of molecular glues requires comprehensive screening strategies including DNA-encoded libraries and high-throughput assays, followed by in vitro and in vivo testing to confirm binding, selectivity, and therapeutic efficacy.

FDA and EMA expectations are shifting from testing-based approval toward demonstrating process understanding, structured data, and documented control strategies that explain why a therapeutic will reliably perform. As pharmaceutical development becomes more distributed across specialized partners, regulatory frameworks are evolving to support coherence and traceability across multiple contributors while enabling modern, knowledge-driven development rather than constraining innovation.

The CDMO market is shifting from large integrated suppliers offering broad capabilities to networks of specialized suppliers, requiring sponsors to exercise greater discipline in partner selection focused on technical depth rather than comprehensive portfolios. Success increasingly depends on structured partner discovery, standardized capability comparison, and centralized coordination that maintains regulatory coherence and operational alignment across distributed development networks.

In the first two installments of this series, we explored 2 major reasons why pharmaceutical development and manufacturing (PharmDev) is being...

Personalized medicine is shifting pharmaceutical development from standardized, high-volume processes to low-volume, high-variability programs where complexity stems from precision science rather than scale. Success increasingly depends on orchestrated networks of specialized partners, continuous process understanding, and faster coordination across distributed ecosystems rather than centralized, broad-capability suppliers.

This blog post was written by FUJIFILM Corporation, a global contract research organization (CRO) providing drug discovery and preclinical services...

Pharmaceutical development is shifting from cost-optimized, centralized supply chains to resilience-focused, regionalized networks driven by geopolitical pressure, economic volatility, and exposed fragility in global manufacturing. Companies now prioritize supply security over unit cost, requiring orchestrated partnerships with multiple qualified suppliers to balance efficiency with the ability to absorb disruptions.

The Biosecure Act decouples U.S. biopharma from designated foreign biotechnology companies of concern, requiring comprehensive supply chain audits and planned transitions across discovery, development, and manufacturing. The five-year grandfathering period enables manageable relocation of critical operations, though clinical manufacturing faces the greatest disruption risk and requires careful coordination to avoid delays and increased costs.

CMC-specific conferences provide concentrated networking and regulatory expertise on specialized pharmaceutical development topics often overlooked at broader biotech events. Key 2026 conferences including Drug Discovery Chemistry, CDMO LIVE, Festival of Biologics, and ChemOutsourcing enable professionals to benchmark strategies and connect with manufacturing and controls decision-makers.

This blog post was written by Medicines Discovery Catapult, an independent drug discovery innovation centre reshaping drug discovery for patient...

This blog post was written by ICE Bioscience, a global contract research organization (CRO) providing preclinical bioscience platforms, focusing on...

Successful biopharma sourcing now requires combining verified regulatory compliance, geographically-diversified partnerships, and data-driven platform tools to navigate the complexity of modern drug development. Integrated platforms like Scientist.com enable organizations to efficiently identify and manage strategic suppliers across discovery, development, and commercialization phases while maintaining compliance and reducing sourcing delays.

This blog post was written by Cresset, a registered Scientist.com supplier that delivers solutions to optimize chemistry R&D innovation and...

Biological material licensing grants researchers the right to use proprietary biological materials containing intellectual property, such as cell lines and organoids, while ensuring legal compliance and protecting IP holder rights. Licensing mitigates risks of cross-contamination and misidentification while maintaining the reproducibility and reliability critical to preclinical research outcomes.

This blog post was written by Nuvalore, a service provider that offers innovative approaches, experienced teams and suitable analytical methods for...

This blog post was written by WuXi AppTec Discovery Services, a service provider that delivers preclinical discoveries through world class...

Within pharmaceutical development, Chemistry, Manufacturing and Controls (CMC) plays a critical role in ensuring that drug products meet regulatory...

This installment of Tech Snapshot was written by Applied Pathology Systems, a CLIA certified laboratory located in Greater Boston that supports...

Scientist.com promotes sustainability by making environmental certifications and emissions reporting freely accessible to suppliers and clients, removing financial barriers that disadvantage smaller companies. The platform provides transparency into supplier sustainability practices while operating with 100% renewable energy internally, enabling informed supplier selection based on environmental commitments rather than relegating sustainability information behind paywalls.

This blog post was written by PharmaBlock, a leading provider of innovative chemistry products and services throughout the pharmaceutical R&D...

This installment of Supplier Spotlight highlights Bellen Chemistry, an integrated Contract Chemistry Service Organization(CCSO) with years of...